Microbiota from fecal samples from IBS-D patients, in combination with vitamin D
supplementation added to our 3-D immunocompetent intestinal models will establish a high
fidelity disease model to achieve our long-term goal to understand the relationship between
gut microbiome, vitamin D levels, host gene expression and IBS-D symptoms that could
ultimately be used as a testing platform for treatment and prevention.
The pathophysiology of IBS is not well understood. Preliminary studies support IBS-D patients
with varied microbiome fingerprints, vitamin D levels, and blood serotonin levels compared to
non-IBS patients. The investigators have novel 3-D immunocompetent intestinal models to
establish a new model of high fidelity disease to examine the relationship of IBS-D patients
gut microbiome, with supplemental vitamin D levels, and the relationship of blood serotonin
and vitamin D levels. IBS-D patients and healthy controls will be asked to provide a fecal
sample, a biopsy sample of colonic tissue obtained during a clinically appropriate flexible
sigmoidoscopy or colonoscopy, and a blood sample. There will be 1-2 office visits. One visit
will last 30 minutes, the second visit no longer than 3 hours. This study is funded by a
combined MAYO-Arizona State University seed grant. The samples will be analyzed at ASU. Our
long-term goal is to understand the relationship between gut microbiome, vitamin D levels,
host gene expression, serotonin levels, and IBS-D symptoms that could ultimately be used as a
testing platform for treatment and prevention of this highly prevalent disorder.
- Patients who fulfill IBS-D criteria, without causes of active inflammation.
- active symptoms for at least 2 months
- diagnosed at least 6 months prior to enrollment
- Healthy control patients should have no active infection or inflammation.
- does not meet inclusion criteria
- will not participate in blood draw, stool sample donation, or endoscopy
- history of acute illness within 3 months of testing
- any fecal transplant history